THCA Therapeutics completed an initial introduction with RA Capital Management. Following review of the company’s investor presentation, RA Capital indicated that they would welcome the opportunity to reconnect once proof-of-concept clinical data become available. This feedback confirmed that future clinical validation will be an important milestone for engaging institutional life science investors.